GoAI
Get started
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc.

PVLA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$142.04

−$0.54 · -0.38%

Aug 21, 4:00 PM ET

PVLA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

25

Expensive

Momentum

73

Gaining

Sentiment

61

Bullish

Risk resilience

60

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Wesley H. Kaupinen
Listed since
Jan 2, 2015
Employees
29

Market position

Day range

Current $142.04

52-week range

Current $142.04

Open
$145.55
Previous close
$142.58
Volume
161.87K
0.67× average
Average volume
240.94K
Average daily volume
Market cap
2.04B USD
Beta
-0.17
Market reference 1
50-day average
$141.46
+0.41% above average
200-day average
$115.26
+23.24% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-29.41×
P/B (TTM)
9.4×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
0×
Altman Z-score
32.82
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends118%14%-90%-194%Gross margin, FY2021: 92.46%Gross margin, FY2022: 89.27%Operating margin, FY2021: -164.97%Operating margin, FY2022: -167.84%Net margin, FY2021: -145.58%Net margin, FY2022: -128.47%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 92.46%. Gross margin FY2022 89.27%. Operating margin FY2021 -164.97%. Operating margin FY2022 -167.84%. Net margin FY2021 -145.58%. Net margin FY2022 -128.47%.

Income trends

Revenue

25.9M USD-17.56%

Operating income

−38.6M USD-173.87%

Net income

−41.72M USD-139.27%
Income trends across reported periods39.74M USD6.44M USD−26.86M USD−60.16M USDRevenue, FY2021: 31.42M USDRevenue, FY2022: 25.9M USDOperating income, FY2021: −51.83M USDOperating income, FY2022: −43.47M USDOperating income, FY2023: −11.87M USDOperating income, FY2024: −14.1M USDOperating income, FY2025: −38.6M USDNet income, FY2021: −45.74M USDNet income, FY2022: −33.28M USDNet income, FY2023: 18.69M USDNet income, FY2024: −17.43M USDNet income, FY2025: −41.72M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 31.42M USD. Revenue FY2022 25.9M USD. Operating income FY2021 −51.83M USD. Operating income FY2022 −43.47M USD. Operating income FY2023 −11.87M USD. Operating income FY2024 −14.1M USD. Operating income FY2025 −38.6M USD. Net income FY2021 −45.74M USD. Net income FY2022 −33.28M USD. Net income FY2023 18.69M USD. Net income FY2024 −17.43M USD. Net income FY2025 −41.72M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue———25.9M USD31.42M USD
Cost of goods sold———2.78M USD2.37M USD
Gross profit———23.12M USD29.05M USD
Research and development22.84M USD8.15M USD8.79M USD50.21M USD64.2M USD
Selling, general, and administrative15.76M USD5.94M USD3.08M USD16.38M USD16.68M USD
Operating expenses38.6M USD14.1M USD11.87M USD66.6M USD80.88M USD
Interest income2.59M USD642K USD6.27M USD721K USD4K USD
Interest expense5.82M USD4.32M USD———
Depreciation and amortization———2.78M USD2.37M USD
Operating income−38.6M USD−14.1M USD−11.87M USD−43.47M USD−51.83M USD
Net income−41.72M USD−17.43M USD18.69M USD−33.28M USD−45.74M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
+115.08%
11 comparable reports
Latest EPS result
-1.52
Estimate -1.17 · Miss by 29.91%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates4.591.73-1.13-3.99Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual 4, estimate -0.39, surprise +1125.64%, Beat. Q2 2025, reported May 15, 2025: actual -0.74, estimate -3.4, surprise +78.24%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.86, estimate -0.78, surprise -10.26%, Miss. Q4 2025, reported Nov 11, 2025: actual -1.03, estimate -0.85, surprise -21.18%, Miss. Q1 2026, reported Mar 31, 2026: actual -1.08, estimate -0.911, surprise -18.53%, Miss. Q2 2026, reported May 7, 2026: actual -1.2, estimate -0.9, surprise -33.33%, Miss. Q3 2026, reported Aug 4, 2026: actual -1.52, estimate -1.17, surprise -29.91%, Miss. Q4 2026, reported Nov 10, 2026: actual —, estimate -1.77, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.42M1.62M816.84K14.17KQ1 '24MissQ2 '24EstimateQ3 '24EstimateQ4 '24EstimateQ4 '26Estimate
Q1 2024, reported Mar 30, 2024: actual 1.3M USD, estimate 2.24M USD, surprise -42.11%, Miss. Q2 2024, reported May 16, 2024: actual —, estimate 2.24M USD, surprise —, Comparison unavailable. Q3 2024, reported Aug 14, 2024: actual —, estimate 2.24M USD, surprise —, Comparison unavailable. Q4 2024, reported Nov 13, 2024: actual —, estimate 1.07M USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 10, 2026: actual —, estimate 16.67K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$231.5

62.98% upside
Past 12 months12-month forecastHigh $270Average $231.5Low $207

Recent analyst actions

11 institutions
Stephens & Co.maintainOverweight
MizuhomaintainOutperform

PVLA news

seekingalpha.com

Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel

Palvella advances QTORIN rapamycin, targeting microcystic lymphatic malformations, with positive Phase 3 SELVA data and a rolling NDA submission underway. PVLA leverages a repeatable regulatory and commercial platform,…

Read source
marketbeat.com

Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands

Palvella Therapeutics NASDAQ: PVLA is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a…

Read source
defenseworld.net

Palvella Therapeutics Q2 Earnings Call Highlights

Palvella Therapeutics (NASDAQ: PVLA) said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half of 2026, with…

Read source
globenewswire.com

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies…

Read source
seekingalpha.com

Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript

Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Palvella Therapeutics Q2 Earnings Call Highlights

Palvella Therapeutics NASDAQ: PVLA said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half of 2026, with…

Read source

Corporate actions

Corporate action history

Stock split

Effective Apr 23, 2024

1:80

PVLA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PVLA

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
61.18M
Weight
0.54%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
54.18M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
39.78M
Weight
0.05%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
14.44M
Weight
0.10%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
8.56M
Weight
0.05%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
4.23M
Weight
0.02%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%
Vanguard U.S. Momentum Factor ETF logoVanguard U.S. Momentum Factor ETFVFMO
Market value
3.51M
Weight
0.18%
AUM
1.8B USD
Expense ratio
0.13%
Price / 1D
$232.52+0.68%
F/M Emerald Life Sciences Innovation ETF logoF/M Emerald Life Sciences Innovation ETFLFSC
Market value
2.49M
Weight
1.92%
AUM
74.65M USD
Expense ratio
0.54%
Price / 1D
$47.7953+0.83%

Continue in GoAI

Research PVLA

research.disclaimer